SCHEMBL14633768

SCHEMBL14633768

CNc1nc(Nc2cc(F)cc(S(C)(=O)=O)c2)ncc1-c1n[nH]c2nc(C)c(F)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.37
JAK1 P23458 3/20 0.36
JAK3 P52333 2/20 0.36
LRRK2 Q5S007 5/20 0.35
CDK2 P24941 7/20 0.35
CDK9 P50750 6/20 0.35
CCNT1 O60563 5/20 0.35
CDK1 P06493 4/20 0.35
CCNB1 P14635 4/20 0.35
CCNA2 P20248 4/20 0.35
CDK7 P50613 3/20 0.35
CCNH P51946 3/20 0.35
CCNE1 P24864 3/20 0.35
CCNB2 O95067 2/20 0.35
CCNB3 Q8WWL7 2/20 0.35
CCNE2 O96020 1/20 0.35
CCNA1 P78396 1/20 0.35
JAK2 O60674 1/20 0.34
PLK4 O00444 1/20 0.34
CDK5 Q00535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471137 0.93 CDK2 (0.36) PTGS2JAK1JAK3LRRK2CDK2
SCHEMBL14634057 0.90 CDK2 (0.38) PTGS2JAK1JAK3LRRK2CDK2
SCHEMBL14634194 0.90 JAK1 (0.47) PTGS2JAK1JAK3CDK2CDK9
SCHEMBL14634260 0.87 JAK2 (0.45) JAK1JAK3CDK2CDK9CCNT1
SCHEMBL14633931 0.85 JAK3 (0.43) JAK1JAK3LRRK2CDK2CDK9
SCHEMBL2434666 0.83 PTGS2 (0.38) PTGS2JAK1JAK3LRRK2CDK2
SCHEMBL14633760 0.82 CCNT1 (0.37) PTGS2JAK1JAK3LRRK2CDK2
SCHEMBL14634045 0.81 JAK1 (0.38) PTGS2JAK1JAK3LRRK2CDK2
SCHEMBL2468649 0.80 SYK (0.45) JAK1JAK3LRRK2CDK2CDK9
SCHEMBL14634113 0.80 IGF1R (0.34) LRRK2CDK2CDK9CCNT1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 PTGS2 2583/4885JAK1 58/4885JAK3 102/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 PTGS2 3295/4885JAK1 93/4885JAK3 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.